NLRP3 and type 2 diabetes mellitus: Tranilast binds directly to the NACHT structural domain of NLRP3 and inhibits the assembly of NLRP3 inflammasome, showing therapeutic effects in gouty arthritis and type 2 diabetes mellitus mouse models.